These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 32358088)
1. PET Imaging Quantifying Cuda TJ; Riddell AD; Liu C; Whitehall VL; Borowsky J; Wyld DK; Burge ME; Ahern E; Griffin A; Lyons NJR; Rose SE; Clark DA; Stevenson ARL; Hooper JD; Puttick S; Thomas PA J Nucl Med; 2020 Nov; 61(11):1576-1579. PubMed ID: 32358088 [TBL] [Abstract][Full Text] [Related]
2. Value of post-therapy Tuncel M; Telli T Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):114-117. PubMed ID: 28750750 [TBL] [Abstract][Full Text] [Related]
3. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298 [TBL] [Abstract][Full Text] [Related]
5. Results of a Prospective Phase 2 Pilot Trial of Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003 [TBL] [Abstract][Full Text] [Related]
6. van Boxtel W; Lütje S; van Engen-van Grunsven ICH; Verhaegh GW; Schalken JA; Jonker MA; Nagarajah J; Gotthardt M; van Herpen CML Theranostics; 2020; 10(5):2273-2283. PubMed ID: 32089741 [No Abstract] [Full Text] [Related]
7. Sathekge M; Bruchertseifer F; Knoesen O; Reyneke F; Lawal I; Lengana T; Davis C; Mahapane J; Corbett C; Vorster M; Morgenstern A Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):129-138. PubMed ID: 30232539 [TBL] [Abstract][Full Text] [Related]
8. Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT. Roll W; Bode A; Weckesser M; Bögemann M; Rahbar K Clin Nucl Med; 2017 Feb; 42(2):152-153. PubMed ID: 27922871 [TBL] [Abstract][Full Text] [Related]
11. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548 [TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
13. Metastases From Colorectal Cancer Avid on 68Ga-PSMA PET/CT. Hangaard L; Jochumsen MR; Vendelbo MH; Bouchelouche K Clin Nucl Med; 2017 Jul; 42(7):532-533. PubMed ID: 28525451 [TBL] [Abstract][Full Text] [Related]
14. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Dietlein M; Kobe C; Kuhnert G; Stockter S; Fischer T; Schomäcker K; Schmidt M; Dietlein F; Zlatopolskiy BD; Krapf P; Richarz R; Neubauer S; Drzezga A; Neumaier B Mol Imaging Biol; 2015 Aug; 17(4):575-84. PubMed ID: 26013479 [TBL] [Abstract][Full Text] [Related]
15. Clinical Translation and First In-Human Use of [ Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832 [TBL] [Abstract][Full Text] [Related]
16. Dosimetry of Violet J; Jackson P; Ferdinandus J; Sandhu S; Akhurst T; Iravani A; Kong G; Kumar AR; Thang SP; Eu P; Scalzo M; Murphy D; Williams S; Hicks RJ; Hofman MS J Nucl Med; 2019 Apr; 60(4):517-523. PubMed ID: 30291192 [No Abstract] [Full Text] [Related]
17. TheraP: a randomized phase 2 trial of Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341 [TBL] [Abstract][Full Text] [Related]
18. Cutaneous, Subcutaneous, and Bilateral Adrenal Gland Metastases in Progressive Prostate Carcinoma: Theranostic Potential of 68 Ga-PSMA-11 PET/CT Imaging and 177 Lu-PSMA-617 Therapy. Parghane RV; Basu S Clin Nucl Med; 2024 Jun; 49(6):587-588. PubMed ID: 38557426 [TBL] [Abstract][Full Text] [Related]
19. Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC: A Proof-of-Principle Application. Bal C; Yadav MP; Ballal S Clin Nucl Med; 2016 Aug; 41(8):e386-7. PubMed ID: 27187728 [TBL] [Abstract][Full Text] [Related]
20. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]